Literature DB >> 3363311

[The use of calcium antagonists in the treatment of ocular circulation symptoms in the framework of a vasospastic syndrome].

P Gasser1, J Flammer, F Mahler.   

Abstract

In a number of patients with etiologically unexplained visual field loss, a vasospastic syndrome was found with the aid of capillaroscopic local cooling test on the fingers. After therapy with calcium entry blockers the visual field of the patients with vasospastic syndrome underwent a marked and statistically significant improvement. The control group showed a slight but statistically insignificant tendency towards improvement.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363311

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  6 in total

1.  Replication of ciliary vasomotor effects with controlled intravascular corrosion casting.

Authors:  E M Van Buskirk; D R Bacon; W F Fahrenbach
Journal:  Trans Am Ophthalmol Soc       Date:  1989

Review 2.  Management of Blood Pressure in Patients with Glaucoma.

Authors:  Russell M Levine; Alina Yang; Venkatesh Brahma; James F Martone
Journal:  Curr Cardiol Rep       Date:  2017-09-19       Impact factor: 2.931

3.  The effect of nifedipine on retinal venous pressure of glaucoma patients with the Flammer-Syndrome.

Authors:  L Fang; S Turtschi; Maneli Mozaffarieh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-12       Impact factor: 3.117

Review 4.  Ocular vasospasm: a risk factor in the pathogenesis of low-tension glaucoma.

Authors:  P Gasser
Journal:  Int Ophthalmol       Date:  1989-07       Impact factor: 2.031

5.  The primary vascular dysregulation syndrome: implications for eye diseases.

Authors:  Josef Flammer; Katarzyna Konieczka; Andreas J Flammer
Journal:  EPMA J       Date:  2013-06-07       Impact factor: 6.543

Review 6.  The discovery of the Flammer syndrome: a historical and personal perspective.

Authors:  Josef Flammer; Katarzyna Konieczka
Journal:  EPMA J       Date:  2017-05-22       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.